Bausch+Lomb IPO Presentation Deck
Top franchises drive revenue growth
PreserVisionⓇ
| Ocuvite
PreserVision
AREDS 2
Ocuvite
50+
Dovile
$351m
Revenue¹
#1 in US²
BAUSCH+ LOMB
BIO
Biotrue Ⓡ
Bio
true
Bio Bio
true true
$336m
Revenue¹
#1 MPS5 in
Canada³
SofLensⓇ
$265m
Revenue¹
#1 in China4
1. For the year ended December 31, 2021
2. For US. Bausch+Lomb Consumer Data Science, IRI Data, Mulo. Latest Data Ending 11-14-21
3. Moving Average Total Oct. 2021. Nielsen, National GB+DR+MM.
4. FY2020. Euromonitor
Renu®
re
nu
**O
re
nu
ROVANCED
FORMULA
$186m
Revenue¹
#1 in China6
and Japan7
Bausch +
Lomb Ultra®
BAUSCH+ LOMB
ULTRA
porad
$170m
Revenue¹
5. Multipurpose solution.
6. FY2019. Third party data,
7. YTD Oct 2021. Intage SRI+ for OTC market (off-take).
Artelac®
Artelac
Rebalance
VISION CARE
hast
Aricket
tyl
$113m
Revenue¹
LumifyⓇ
LUMIFY
LITTIES
$108m
Revenue ¹
#1 in US²
19View entire presentation